Astrazeneca PLC (AZN): Price and Financial Metrics


Astrazeneca PLC (AZN)

Today's Latest Price: $42.47 USD

0.11 (0.26%)

Updated Mar 27 12:00am

Add AZN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AZN Stock Summary

  • AZN has a higher market value than 98.77% of US stocks; more precisely, its current market capitalization is $106,395,780,000.
  • With a price/earnings ratio of 86.71, Astrazeneca Plc P/E ratio is greater than that of about 95.3% of stocks in our set with positive earnings.
  • In terms of volatility of its share price, AZN is more volatile than merely 6.49% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Astrazeneca Plc are NVO, SNY, GSK, AMGN, and BMY.
  • AZN's SEC filings can be seen here. And to visit Astrazeneca Plc's official web site, go to www.astrazeneca.com.
AZN Daily Price Range
AZN 52-Week Price Range

AZN Stock Price Chart More Charts


AZN Price/Volume Stats

Current price $42.47 52-week high $51.55
Prev. close $42.36 52-week low $36.15
Day low $40.69 Volume 6,783,100
Day high $43.13 Avg. volume 4,125,626
50-day MA $46.56 Dividend yield 4.38%
200-day MA $45.54 Market Cap 111.46B

Astrazeneca PLC (AZN) Company Bio


AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$42.47$15.07-64%

We started the process of determining a valid price forecast for Astrazeneca Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Astrazeneca Plc ranked in the 19th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 64.17%. In terms of the factors that were most noteworthy in this DCF analysis for AZN, they are:

  • The company's compound free cash flow growth rate over the past 5.81 years comes in at -0.12%; that's greater than only 15.57% of US stocks we're applying DCF forecasting to.
  • The weighted average cost of capital for the company is 7. This value is greater than just 21.45% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-65%
1%-65%
2%-64%
3%-64%
4%-64%
5%-63%

DHR, EW, TFX, CNMD, and HOLX can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


AZN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AZN Latest Social Stream


Loading social stream, please wait...

View Full AZN Social Stream

AZN Price Returns

1-mo -5.77%
3-mo -14.12%
6-mo -2.81%
1-year 8.22%
3-year 50.84%
5-year 47.58%
YTD -13.12%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%
2015 0.51%

AZN Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7491 seconds.